FDA Grants Fast Track Designation to ISB 2001 in Relapsed/Refractory Multiple Myeloma

IGI’s relapsed/refractory multiple myeloma drug wins fast track status

The U.S. Food and Drug Administration (FDA) has granted fast track status to ISB 2001, an experimental therapy for difficult-to-treat multiple myeloma. The designation covers the use of ISB 2001 in people with myeloma that is relapsed or refractory, meaning the disease has come back or failed to respond, after at least three prior lines of treatment that include an immunomodulatory medication, a proteasome inhibitor, and an anti-CD38 antibody. T…

Givinostat Wins U.S. FDA Fast Track Designation for Patients With PV

Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for patients with polycythemia vera.

FDA Grants Fast Track Designation to ISB 2001 in Relapsed/Refractory Multiple Myeloma

ISB 2001 has received fast track designation from the FDA for patients with relapsed or refractory multiple myeloma who received 3 or more prior therapies.

FDA Grants ISB 2001 Fast Track Designation in RRMM

Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of relapsed/refractory multiple myeloma.